Kailera Therapeutics · 13 hours ago
Associate Director, Statistical Programming
Kailera is committed to developing therapies that empower individuals to enhance their health. They are seeking an Associate Director, Statistical Programming to lead statistical programming activities for clinical trials and regulatory submissions.
BiotechnologyPharmaceuticalTherapeutics
Responsibilities
Lead statistical programming efforts for clinical studies, including the development and review of programming specifications to ensure clarity, integrity, and compliance with internal and external standards
Oversee and coordinate activities with Contract Research Organizations (CROs), focusing on the implementation of CDISC standards, creation of SDTM, ADaM datasets, and TFLs, and ensuring high-quality deliverables
Conduct independent validation and quality checks of statistical programming deliverables from CROs
Collaborate closely with statisticians and cross-functional study teams to deliver results in a timely and accurate manner
Manage multiple projects simultaneously, ensuring tasks are prioritized effectively to meet deadlines
Qualification
Required
Minimum of 7+ years of relevant experience with MS, 5+ years of relevant experience with PhD
Proven hands-on experience in programming for clinical development, preferably in a leadership role, with a strong preference for late-phase clinical trial support
Experience in regulatory submissions, including NDAs, BLAs, and other filings, with experience in ISS/ISE highly desirable
Expertise in SAS programming and comprehensive knowledge of CDISC standards
Familiarity with ICH/GCP guidelines and global regulatory submission requirements (e.g., FDA, EMA)
Extensive experience overseeing CROs, including independent validation of datasets and statistical deliverables
Advanced degree (MS/PhD) in Biostatistics, Statistics, or a related field
Preferred
Background in cardiometabolic diseases or related therapeutic areas is preferred
Benefits
Comprehensive health coverage
Flexible time off
Paid holidays
Year-end shutdown
Monthly wellness stipend
Generous 401(k) match
Tuition reimbursement
Commuter benefits
Disability and life insurance
Annual bonus opportunities
Equity grants
Company
Kailera Therapeutics
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Funding
Current Stage
Growth StageTotal Funding
$1BKey Investors
Bain Capital Private Equity
2025-10-14Series B· $600M
2024-10-01Series A· $400M
Recent News
2025-12-24
2025-12-17
2025-12-16
Company data provided by crunchbase